An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

Bibliography

• Hatzimouratidis K, Amar E, Eardley I, et al. European association of urology. guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, et al. Oral Sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 1998;338:1397-404
   PubMed Web of Science ®Google Scholar
• Bell AS, Palmer MJ. Novel phosphodiesterase type 5 modulators: 481 a patent survey (2008–2010). Expert Opin Ther Pat 2011;21:482 1631-41
   Google Scholar
• Aversa A, Bruzziches R, Pili M, et al. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-84
   PubMed Web of Science ®Google Scholar
• Hatzichristou D, Rosen RC, Broderick G, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004;1:4957
   Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Ther Adv Urol 2009;1:179-97
   PubMedGoogle Scholar
• Hatzimouratidis K. Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance? J Men's Health Gender 2006;3:342-9
   Google Scholar
• McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332:589-92
   PubMed Web of Science ®Google Scholar
• Son H, Park K, Kim SW, et al. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004;6:117-20
   PubMed Web of Science ®Google Scholar
• Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005;7:57-65
   PubMedGoogle Scholar
• Aversa A, Jannini EA, Maggi M, Lenzi A. Effects of testosterone replacement on response to sildenafil citrate. Ann Intern Med 2013;158:569-70
   PubMedGoogle Scholar
• Aversa A. Drugs targeted to improve endothelial function: clinical correlates between sexual and internal medicine. Curr Pharm Des 2008;14:3698-9
   PubMedGoogle Scholar
• Aversa A, Caprio M, Rosano GM, et al. Endothelial effects of drugs designed to treat erectile dysfunction. Curr Pharm Des 2008;14:3768-78
   PubMedGoogle Scholar
• McMahon CG. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300
   PubMed Web of Science ®Google Scholar
• Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo controlled trial. Eur Urol 2006;50:351-9
   PubMed Web of Science ®Google Scholar
• McMahon CG. Comparison, efficacy, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005;2:415-25
   PubMed Web of Science ®Google Scholar
• Rosano GM, Aversa A, Vitale C, et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-22
   PubMed Web of Science ®Google Scholar
• Porst H, Brock GB, Kula K, et al. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl 2012;33:1305-22
   PubMedGoogle Scholar
• Shindel AW. 2009 Update on phosphodiesterase type 5 inhibitor therapy Part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications. J Sex Med 2009;6:1794-808
   PubMed Web of Science ®Google Scholar
• Giannetta E, Isidori AM, Galea N, et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012;125(19):2323-33
   PubMed Web of Science ®Google Scholar
• Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25
   PubMed Web of Science ®Google Scholar
• Francis SH, Busch JL, Corbin JD, et al. CGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010;62:525-63
   PubMed Web of Science ®Google Scholar
• Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium- dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005;47:87-91
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Vitale C, et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007;3:451-64
   PubMed Web of Science ®Google Scholar
• Kanwar M, Agarwal R, Barnes M, et al. Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. Curr Heart Fail Rep 2013;10:26-35
   PubMedGoogle Scholar
• Tignol J, Furlan PM, Gomez-Beneyto M, et al. Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in 585 remission from depression. Int Clin Psychopharmacol 2004;19:191-9
   PubMed Web of Science ®Google Scholar
• Rosato E, Letizia C, Proietti M, et al. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis. J Biol Regul Homeost Agents 2009;23:23-9
   PubMedGoogle Scholar
• Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a 593 double-blind, placebo controlled, randomized study. J Urol 2009;181:252-8
   PubMedGoogle Scholar
• Basu A, Ryder RE. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004;64:2667-88
   PubMedGoogle Scholar
• Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006;60:967-75
   PubMed Web of Science ®Google Scholar
• Fabbri A, Aversa A, Isidori A. Sildenafil and erectile dysfunction. J Endocrinol Invest 1999;22(6):486-92
   PubMedGoogle Scholar
• Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10(2):69-73
   PubMedGoogle Scholar
• Aversa A, Bruzziches R, Vitale C, et al. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007;3:451-64
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003;92(9A):19M-25M
   Google Scholar
• Porst H, Padma-Nathan H, Giuliano F, et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 2003;62:121-6
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Eardley I, Whitaker S, et al. Time distribution of sexual intercourse attempts after taking tadalafil or placebo. Int J Impot Res 2003;15(suppl 5):S177
   Google Scholar
• Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004;45:339-44
   PubMed Web of Science ®Google Scholar
• Weeks JL II, Zoraghi R, Beasley A, et al. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005;17:5-9
   PubMed Web of Science ®Google Scholar
• Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855-60
   PubMed Web of Science ®Google Scholar
• Bruzziches R, Greco EA, Pili M, et al. Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. Curr Diabetes Rev 2008;4:24-30
   PubMedGoogle Scholar
• Giuliano F, Oelke M, Jungwirth A, et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med 2013; doi: 10.1111/jsm.12039; [Epub ahead of print]
   Google Scholar
• Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004(16 Suppl 1):34-7
   Google Scholar
• Hellstrom WJ. Vardenafil. a new approach to the treatment of erectile dysfunction. Curr Urolol Rep 2003;4:479-87
   PubMedGoogle Scholar
• Goldstein I, Young JM, Fischer J, et al. Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83
   PubMed Web of Science ®Google Scholar
• Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. Urology 2003;170(4 Pt 1):1278-83
   Google Scholar
• Jannini EA, McMahon C, Chen J, et al. The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. J Sex Med 2011;8:2135-43
   PubMed Web of Science ®Google Scholar
• Heinig R, Weimann B, Dietrich H, et al. Pharmacokinetics of a new orodispersible table formulation of vardenafil: results of three clinical trials. Clin Drug Invest 2011;31:27-41
   PubMed Web of Science ®Google Scholar
• Sanford M. Vardenafil orodispersible tablet. Drugs 2012;72:87-98
   PubMed Web of Science ®Google Scholar
• Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010;7(4 Pt 1):1497-507
   PubMedGoogle Scholar
• Gittelman M, McMahon CG, Rodriguez-Rivera JA, et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010;64:594-603
   PubMed Web of Science ®Google Scholar
• Salem EA, Kendirci M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006;7:661-9
   PubMedGoogle Scholar
• Ding H, Du W, Wang H, et al. Efficacy and safety of udenafil for erectile dysfunction: a metaanalysis of randomized controlled trials. Urology 2012;80:134-9
   PubMedGoogle Scholar
• US Food and Drug Administration. FDA approves Stendra for erectile dysfunction. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm [Accessed 1 May2012]
   Google Scholar
• Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Dev Ther 2011;5:435-43
   PubMed Web of Science ®Google Scholar
• Burke RM, Evans JD. Avanafil for treatment of erectile dysfunction: review of its potential. Vasc Health Risk Manag 2012;8:517-23
   PubMedGoogle Scholar
• Kim BH, Yi S, Kim J, et al. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized- sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Ther 2009;31:1234
   PubMed Web of Science ®Google Scholar
• Shin HI, Lee J, Kim DK. Synthesis of 5-ethyl-2-{5- [4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-npropoxyphenyl}-7-n-propyl-3,5-dihydro-4Hpyrrolo[3,2-d]-[2-14C]pyrimidin-4-one·2HCl (14CSK3530. 2 HCl). J Labelled Comp Radiopharm 2006;49:1141-9
   Google Scholar
• Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4- (2-hydroxyethyl) piperazine-1-sulfonyl]-2- propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK 3530) in rats. Rapid Commun Mass Spectrom 2007;21:1139-49
   PubMed Web of Science ®Google Scholar
• Paick JS, Choi HK, Kim SC, et al. Efficacy and safety of oral SK3530 in the treatment of men in Korea with erectile dysfunction: a multicentre, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. J Sex Med 2006;3(5 suppl):393
   Google Scholar
• Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral Phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5:2672
   PubMed Web of Science ®Google Scholar
• Jannini EA, Isidori AM, Gravina GL, et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med 2009;6:2547-60
   PubMed Web of Science ®Google Scholar
• Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 2012;9:1418-29
   PubMed Web of Science ®Google Scholar
• Buvat J, Büttner H, Hatzimouratidis K, et al. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 2013; Epub ahead of print
   Google Scholar
• Yoo C, Park J, Kim W, et al. Comparison of the efficacy, safety and patient preference of the phosphodiesterase type 5 inhibitors for the patients with erectile dysfunction. Korean J Urol 2007;48:219-25
   Google Scholar
• Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23
   PubMed Web of Science ®Google Scholar
• Moore R, Derry S, McQuay H. Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005;5:18
   PubMedGoogle Scholar
• Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650-61
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Phosphodiesterase 5 inhibitors: a review of the clinical effectiveness and cost-effectiveness. In: CAfDaTi, editor. Health. Ottawa: 2010
   Google Scholar
• Yuan J, Zhang R, Yang Z, et al. The comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: 5 a systematic review and network meta-analysis. Eur Urol 2013; doi: 10.1016/j.eururo.2013.01.012; [Epub ahead of print]
   PubMedGoogle Scholar
• Ljunggren C, Hedelin H, Salomonsson K, et al. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2008;5:469-75
   PubMed Web of Science ®Google Scholar
• Klotz T, Mathers M, Klotz R, et al. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int J Impot Res 2005;17:2-4
   PubMed Web of Science ®Google Scholar
• Son H, Park K, Kim SC, et al. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J Androl 2004;6:117-20
   PubMed Web of Science ®Google Scholar
• Jiann B, Yu C, Su C, et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006;18:146-9
   PubMed Web of Science ®Google Scholar
• Salonia A, Gallina A, Zanni G, et al. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nervesparing radical prostatectomy. Eur Urol 2008;53:564-70
   PubMed Web of Science ®Google Scholar
• Carvalheira AA, Pereira NM, Maroco J, et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361-9
   PubMed Web of Science ®Google Scholar
• Corona G, Mondaini N, Ungar A, et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: The proper drug for the proper patient. J Sex Med 2011;8:3418-32
   PubMed Web of Science ®Google Scholar
• Jannini EA, DeRogatis LR, Chung E, Brock GB. How to evaluate the efficacy of PDE5 inhibitors. J Sex Med 2012;9:26-33
   PubMed Web of Science ®Google Scholar
• Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-15
   PubMed Web of Science ®Google Scholar
• Shiri R, Koskimaki J, Hakkinen J, et al. Tampere Ageing Male Urological Study. Effects of age, comorbidity and lifestyle factors on erectile function: tampere Ageing Male Urological Study (TAMUS). Eur Urol 2004;45:628-33
   PubMed Web of Science ®Google Scholar
• Sharlip ID, Shumaker BP, Hakim LS, et al. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States. J Sex Med 2008;5:716-25
   PubMed Web of Science ®Google Scholar
• Francomano D, Bruzziches R, Natali M, et al. Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed 2010;81:Suppl 1:101-6
   PubMedGoogle Scholar
• McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332:589-92
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005;65:1621-50
   PubMed Web of Science ®Google Scholar
• Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301
   PubMed Web of Science ®Google Scholar
• El-Sakka AI. Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors. Expert Opin Investig Drugs 2011;20:1305-9
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Endothelial dysfunction and erectile dysfunction in the aging man. Int J Urol 2010;17:38-47
   PubMed Web of Science ®Google Scholar
• Nehra A, Jackson J, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012;87:766-78
   PubMed Web of Science ®Google Scholar
• Shon JH, Ku HY, Bae SY, et al. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics 2011;21:820-8
   PubMedGoogle Scholar
• Borer J, Armstrong P. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee; May 29th and 30th, 2003; Circulation 2003. 107: e9052
   Google Scholar
• Porst H, Brock GB, Kula K, et al. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. J Androl 2012;33:1305-22
   PubMedGoogle Scholar
• Aversa A, Pili M, Francomano D, et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 2009;21:221-7
   PubMed Web of Science ®Google Scholar
• Francomano D, Donini LM, Lenzi A, Aversa A. Peripheral arterial tonometry to measure the effects of Vardenafil on sympathetic tone in men with lifelong premature ejaculation. Int J Endocrinol, 2013.2013, Article ID 394934, 9 pages. Available from: http://dx.doi.org/10.1155/2013/394934
   Google Scholar